APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Orphan Drug Development

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Orphan Drug Development Market Analysis and Forecast 2026-2032

Report ID 17420778022 May 2026197 pages

Choose your research edition.

Industry ResearchOrphan Drug Development Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Orphan Drug Development Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Orphan Drug Development Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Orphan Drug Development Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Orphan Drug Development Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Orphan Drug Development market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Orphan Drug Development is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Orphan Drug Development is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Orphan Drug Development is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Orphan Drug Development is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Orphan Drug Development include Novartis, Roche, Celgene, BMS, Shire, Merck, J&J, Pfizer and Biogen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Orphan Drug Development, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Orphan Drug Development, also provides the revenue of main regions and countries. Of the upcoming market potential for Orphan Drug Development, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Orphan Drug Development revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Orphan Drug Development market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Orphan Drug Development revenue, projected growth trends, production technology, application and end-user industry.

Orphan Drug Development Segment by Company

Novartis

Roche

Celgene

BMS

Shire

Merck

J&J

Pfizer

Biogen

Sanofi

AstraZeneca

Takeda

Orphan Drug Development Segment by Type

Pediatric Orphan Drugs

Adult Orphan Drugs

Orphan Drug Development Segment by Application

Congenital and Genetic Diseases

Tumors and Cancer

Endocrine Diseases

Others

Orphan Drug Development Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orphan Drug Development market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Orphan Drug Development and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orphan Drug Development.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Orphan Drug Development in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Orphan Drug Development company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Orphan Drug Development revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Orphan Drug Development Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Pediatric Orphan Drugs Major Player Table 3. Adult Orphan Drugs Major Player Table 4. Global Orphan Drug Development Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Congenital and Genetic Diseases Major Player Table 6. Tumors and Cancer Major Player Table 7. Endocrine Diseases Major Player Table 8. Others Major Player Table 9. Orphan Drug Development Industry Trends Table 10. Orphan Drug Development Industry Drivers Table 11. Orphan Drug Development Industry Opportunities and Challenges Table 12. Orphan Drug Development Industry Restraints Table 13. Global Orphan Drug Development Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Orphan Drug Development Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Orphan Drug Development Market Share by Region (2021-2026) Table 16. Global Orphan Drug Development Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Orphan Drug Development Market Share by Region (2027-2032) Table 18. Global Orphan Drug Development Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Orphan Drug Development Revenue Market Share by Players (2021-2026) Table 20. Global Orphan Drug Development Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Orphan Drug Development Key Players Headquarters & Area Served Table 22. Global Orphan Drug Development Players, Product Type & Application Table 23. Global Orphan Drug Development Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Orphan Drug Development by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Orphan Drug Development Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Orphan Drug Development Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Orphan Drug Development Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Orphan Drug Development Revenue Market Share by Type (2021-2026) Table 30. Global Orphan Drug Development Revenue Market Share by Type (2027-2032) Table 31. Global Orphan Drug Development Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Orphan Drug Development Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Orphan Drug Development Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Orphan Drug Development Revenue Market Share by Application (2021-2026) Table 35. Global Orphan Drug Development Revenue Market Share by Application (2027-2032) Table 36. Novartis Company Information Table 37. Novartis Business Overview Table 38. Novartis Orphan Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Novartis Orphan Drug Development Product Portfolio Table 40. Novartis Recent Development Table 41. Roche Company Information Table 42. Roche Business Overview Table 43. Roche Orphan Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Roche Orphan Drug Development Product Portfolio Table 45. Roche Recent Development Table 46. Celgene Company Information Table 47. Celgene Business Overview Table 48. Celgene Orphan Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Celgene Orphan Drug Development Product Portfolio Table 50. Celgene Recent Development Table 51. BMS Company Information Table 52. BMS Business Overview Table 53. BMS Orphan Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. BMS Orphan Drug Development Product Portfolio Table 55. BMS Recent Development Table 56. Shire Company Information Table 57. Shire Business Overview Table 58. Shire Orphan Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Shire Orphan Drug Development Product Portfolio Table 60. Shire Recent Development Table 61. Merck Company Information Table 62. Merck Business Overview Table 63. Merck Orphan Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Merck Orphan Drug Development Product Portfolio Table 65. Merck Recent Development Table 66. J&J Company Information Table 67. J&J Business Overview Table 68. J&J Orphan Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. J&J Orphan Drug Development Product Portfolio Table 70. J&J Recent Development Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer Orphan Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Pfizer Orphan Drug Development Product Portfolio Table 75. Pfizer Recent Development Table 76. Biogen Company Information Table 77. Biogen Business Overview Table 78. Biogen Orphan Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Biogen Orphan Drug Development Product Portfolio Table 80. Biogen Recent Development Table 81. Sanofi Company Information Table 82. Sanofi Business Overview Table 83. Sanofi Orphan Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Sanofi Orphan Drug Development Product Portfolio Table 85. Sanofi Recent Development Table 86. AstraZeneca Company Information Table 87. AstraZeneca Business Overview Table 88. AstraZeneca Orphan Drug Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. AstraZeneca Orphan Drug Development Product Portfolio Table 90. AstraZeneca Recent Development Table 91. Takeda Company Information Table 92. Takeda Business Overview Table 93. Takeda Orphan Drug Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Takeda Orphan Drug Development Product Portfolio Table 95. Takeda Recent Development Table 96. North America Orphan Drug Development Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Orphan Drug Development Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Orphan Drug Development Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Orphan Drug Development Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Orphan Drug Development Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Orphan Drug Development Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Orphan Drug Development Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Orphan Drug Development Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Orphan Drug Development Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Orphan Drug Development Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Orphan Drug Development Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Orphan Drug Development Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Orphan Drug Development Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Orphan Drug Development Revenue by Country (US$ Million) & (2027-2032) Table 110. China Orphan Drug Development Revenue by Type (2021-2026) & (US$ Million) Table 111. China Orphan Drug Development Revenue by Type (2027-2032) & (US$ Million) Table 112. China Orphan Drug Development Revenue by Application (2021-2026) & (US$ Million) Table 113. China Orphan Drug Development Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Orphan Drug Development Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Orphan Drug Development Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Orphan Drug Development Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Orphan Drug Development Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Orphan Drug Development Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Orphan Drug Development Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Orphan Drug Development Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Orphan Drug Development Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Orphan Drug Development Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Orphan Drug Development Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Orphan Drug Development Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Orphan Drug Development Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Orphan Drug Development Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Orphan Drug Development Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Orphan Drug Development Image Figure 2. Global Orphan Drug Development Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Orphan Drug Development Market Size Share 2021 VS 2025 VS 2032 Figure 4. Pediatric Orphan Drugs Image Figure 5. Adult Orphan Drugs Image Figure 6. Global Orphan Drug Development Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Orphan Drug Development Market Size Share 2021 VS 2025 VS 2032 Figure 8. Congenital and Genetic Diseases Image Figure 9. Tumors and Cancer Image Figure 10. Endocrine Diseases Image Figure 11. Others Image Figure 12. Global Orphan Drug Development Market Size (US$ Million) & (2021-2032) Figure 13. Global Orphan Drug Development Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Orphan Drug Development Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Orphan Drug Development Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Orphan Drug Development Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Orphan Drug Development Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Orphan Drug Development Revenue Market Share by Type (2021-2032) Figure 20. Global Orphan Drug Development Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Orphan Drug Development Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Orphan Drug Development Revenue Market Share by Application (2021-2032) Figure 23. North America Orphan Drug Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Orphan Drug Development Revenue Share by Type (2021-2032) Figure 25. North America Orphan Drug Development Revenue Share by Application (2021-2032) Figure 26. North America Orphan Drug Development Revenue Share by Country (2021-2032) Figure 27. United States Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Orphan Drug Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Orphan Drug Development Revenue Share by Type (2021-2032) Figure 32. Europe Orphan Drug Development Revenue Share by Application (2021-2032) Figure 33. Europe Orphan Drug Development Revenue Share by Country (2021-2032) Figure 34. Germany Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Orphan Drug Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Orphan Drug Development Revenue Share by Type (2021-2032) Figure 44. China Orphan Drug Development Revenue Share by Application (2021-2032) Figure 45. Asia Orphan Drug Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Orphan Drug Development Revenue Share by Type (2021-2032) Figure 47. Asia Orphan Drug Development Revenue Share by Application (2021-2032) Figure 48. Asia Orphan Drug Development Revenue Share by Region (2021-2032) Figure 49. Japan Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Orphan Drug Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Orphan Drug Development Revenue Share by Type (2021-2032) Figure 57. SAMEA Orphan Drug Development Revenue Share by Application (2021-2032) Figure 58. SAMEA Orphan Drug Development Revenue Share by Country (2021-2032) Figure 59. Brazil Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Orphan Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Pediatric Orphan Drugs
  • Adult Orphan Drugs
Applications
  • Congenital and Genetic Diseases
  • Tumors and Cancer
  • Endocrine Diseases
  • Others
Companies covered
  • Novartis
  • Roche
  • Celgene
  • BMS
  • Shire
  • Merck
  • J&J
  • Pfizer
  • Biogen
  • Sanofi
  • AstraZeneca
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Orphan Drug Development Market by Type
  3. 1.2.1 Global Orphan Drug Development Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Pediatric Orphan Drugs
  5. 1.2.3 Adult Orphan Drugs
  6. 1.3 Orphan Drug Development Market by Application
  7. 1.3.1 Global Orphan Drug Development Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Congenital and Genetic Diseases
  9. 1.3.3 Tumors and Cancer
  10. 1.3.4 Endocrine Diseases
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Orphan Drug Development Market Dynamics
  1. 2.1 Orphan Drug Development Industry Trends
  2. 2.2 Orphan Drug Development Industry Drivers
  3. 2.3 Orphan Drug Development Industry Opportunities and Challenges
  4. 2.4 Orphan Drug Development Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Orphan Drug Development Market Perspective (2021-2032)
  2. 3.2 Global Orphan Drug Development Growth Trends by Region
  3. 3.2.1 Global Orphan Drug Development Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Orphan Drug Development Market Size by Region (2021-2026)
  5. 3.2.3 Global Orphan Drug Development Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Orphan Drug Development Revenue by Players
  2. 4.1.1 Global Orphan Drug Development Revenue by Players (2021-2026)
  3. 4.1.2 Global Orphan Drug Development Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Orphan Drug Development Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Orphan Drug Development Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Orphan Drug Development Key Players Headquarters & Area Served
  7. 4.4 Global Orphan Drug Development Players, Product Type & Application
  8. 4.5 Global Orphan Drug Development Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Orphan Drug Development Market CR5 and HHI
  11. 4.6.3 2025 Orphan Drug Development Tier 1, Tier 2, and Tier 3
5 Orphan Drug Development Market Size by Type
  1. 5.1 Global Orphan Drug Development Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Orphan Drug Development Revenue by Type (2021-2032)
  3. 5.3 Global Orphan Drug Development Revenue Market Share by Type (2021-2032)
6 Orphan Drug Development Market Size by Application
  1. 6.1 Global Orphan Drug Development Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Orphan Drug Development Revenue by Application (2021-2032)
  3. 6.3 Global Orphan Drug Development Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Orphan Drug Development Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Orphan Drug Development Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Roche
  8. 7.2.1 Roche Company Information
  9. 7.2.2 Roche Business Overview
  10. 7.2.3 Roche Orphan Drug Development Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Roche Orphan Drug Development Product Portfolio
  12. 7.2.5 Roche Recent Developments
  13. 7.3 Celgene
  14. 7.3.1 Celgene Company Information
  15. 7.3.2 Celgene Business Overview
  16. 7.3.3 Celgene Orphan Drug Development Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Celgene Orphan Drug Development Product Portfolio
  18. 7.3.5 Celgene Recent Developments
  19. 7.4 BMS
  20. 7.4.1 BMS Company Information
  21. 7.4.2 BMS Business Overview
  22. 7.4.3 BMS Orphan Drug Development Revenue and Gross Margin (2021-2026)
  23. 7.4.4 BMS Orphan Drug Development Product Portfolio
  24. 7.4.5 BMS Recent Developments
  25. 7.5 Shire
  26. 7.5.1 Shire Company Information
  27. 7.5.2 Shire Business Overview
  28. 7.5.3 Shire Orphan Drug Development Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Shire Orphan Drug Development Product Portfolio
  30. 7.5.5 Shire Recent Developments
  31. 7.6 Merck
  32. 7.6.1 Merck Company Information
  33. 7.6.2 Merck Business Overview
  34. 7.6.3 Merck Orphan Drug Development Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Merck Orphan Drug Development Product Portfolio
  36. 7.6.5 Merck Recent Developments
  37. 7.7 J&J
  38. 7.7.1 J&J Company Information
  39. 7.7.2 J&J Business Overview
  40. 7.7.3 J&J Orphan Drug Development Revenue and Gross Margin (2021-2026)
  41. 7.7.4 J&J Orphan Drug Development Product Portfolio
  42. 7.7.5 J&J Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Orphan Drug Development Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Orphan Drug Development Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 Biogen
  50. 7.9.1 Biogen Company Information
  51. 7.9.2 Biogen Business Overview
  52. 7.9.3 Biogen Orphan Drug Development Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Biogen Orphan Drug Development Product Portfolio
  54. 7.9.5 Biogen Recent Developments
  55. 7.10 Sanofi
  56. 7.10.1 Sanofi Company Information
  57. 7.10.2 Sanofi Business Overview
  58. 7.10.3 Sanofi Orphan Drug Development Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Sanofi Orphan Drug Development Product Portfolio
  60. 7.10.5 Sanofi Recent Developments
  61. 7.11 AstraZeneca
  62. 7.11.1 AstraZeneca Company Information
  63. 7.11.2 AstraZeneca Business Overview
  64. 7.11.3 AstraZeneca Orphan Drug Development Revenue and Gross Margin (2021-2026)
  65. 7.11.4 AstraZeneca Orphan Drug Development Product Portfolio
  66. 7.11.5 AstraZeneca Recent Developments
  67. 7.12 Takeda
  68. 7.12.1 Takeda Company Information
  69. 7.12.2 Takeda Business Overview
  70. 7.12.3 Takeda Orphan Drug Development Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Takeda Orphan Drug Development Product Portfolio
  72. 7.12.5 Takeda Recent Developments
8 North America
  1. 8.1 North America Orphan Drug Development Revenue (2021-2032)
  2. 8.2 North America Orphan Drug Development Revenue by Type (2021-2032)
  3. 8.2.1 North America Orphan Drug Development Revenue by Type (2021-2026)
  4. 8.2.2 North America Orphan Drug Development Revenue by Type (2027-2032)
  5. 8.3 North America Orphan Drug Development Revenue Share by Type (2021-2032)
  6. 8.4 North America Orphan Drug Development Revenue by Application (2021-2032)
  7. 8.4.1 North America Orphan Drug Development Revenue by Application (2021-2026)
  8. 8.4.2 North America Orphan Drug Development Revenue by Application (2027-2032)
  9. 8.5 North America Orphan Drug Development Revenue Share by Application (2021-2032)
  10. 8.6 North America Orphan Drug Development Revenue by Country
  11. 8.6.1 North America Orphan Drug Development Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Orphan Drug Development Revenue by Country (2021-2026)
  13. 8.6.3 North America Orphan Drug Development Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Orphan Drug Development Revenue (2021-2032)
  2. 9.2 Europe Orphan Drug Development Revenue by Type (2021-2032)
  3. 9.2.1 Europe Orphan Drug Development Revenue by Type (2021-2026)
  4. 9.2.2 Europe Orphan Drug Development Revenue by Type (2027-2032)
  5. 9.3 Europe Orphan Drug Development Revenue Share by Type (2021-2032)
  6. 9.4 Europe Orphan Drug Development Revenue by Application (2021-2032)
  7. 9.4.1 Europe Orphan Drug Development Revenue by Application (2021-2026)
  8. 9.4.2 Europe Orphan Drug Development Revenue by Application (2027-2032)
  9. 9.5 Europe Orphan Drug Development Revenue Share by Application (2021-2032)
  10. 9.6 Europe Orphan Drug Development Revenue by Country
  11. 9.6.1 Europe Orphan Drug Development Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Orphan Drug Development Revenue by Country (2021-2026)
  13. 9.6.3 Europe Orphan Drug Development Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Orphan Drug Development Revenue (2021-2032)
  2. 10.2 China Orphan Drug Development Revenue by Type (2021-2032)
  3. 10.2.1 China Orphan Drug Development Revenue by Type (2021-2026)
  4. 10.2.2 China Orphan Drug Development Revenue by Type (2027-2032)
  5. 10.3 China Orphan Drug Development Revenue Share by Type (2021-2032)
  6. 10.4 China Orphan Drug Development Revenue by Application (2021-2032)
  7. 10.4.1 China Orphan Drug Development Revenue by Application (2021-2026)
  8. 10.4.2 China Orphan Drug Development Revenue by Application (2027-2032)
  9. 10.5 China Orphan Drug Development Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Orphan Drug Development Revenue (2021-2032)
  2. 11.2 Asia Orphan Drug Development Revenue by Type (2021-2032)
  3. 11.2.1 Asia Orphan Drug Development Revenue by Type (2021-2026)
  4. 11.2.2 Asia Orphan Drug Development Revenue by Type (2027-2032)
  5. 11.3 Asia Orphan Drug Development Revenue Share by Type (2021-2032)
  6. 11.4 Asia Orphan Drug Development Revenue by Application (2021-2032)
  7. 11.4.1 Asia Orphan Drug Development Revenue by Application (2021-2026)
  8. 11.4.2 Asia Orphan Drug Development Revenue by Application (2027-2032)
  9. 11.5 Asia Orphan Drug Development Revenue Share by Application (2021-2032)
  10. 11.6 Asia Orphan Drug Development Revenue by Country
  11. 11.6.1 Asia Orphan Drug Development Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Orphan Drug Development Revenue by Country (2021-2026)
  13. 11.6.3 Asia Orphan Drug Development Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Orphan Drug Development Revenue (2021-2032)
  2. 12.2 SAMEA Orphan Drug Development Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Orphan Drug Development Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Orphan Drug Development Revenue by Type (2027-2032)
  5. 12.3 SAMEA Orphan Drug Development Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Orphan Drug Development Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Orphan Drug Development Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Orphan Drug Development Revenue by Application (2027-2032)
  9. 12.5 SAMEA Orphan Drug Development Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Orphan Drug Development Revenue by Country
  11. 12.6.1 SAMEA Orphan Drug Development Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Orphan Drug Development Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Orphan Drug Development Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst